ArticleIndian journal of ophthalmology2021
Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis and management of ethambutol-induced optic neuropathy.
Article in Indian journal of ophthalmology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Ethambutol optic neuropathy in the extended anti-tubercular therapy regime: A systematic review.Indian journal of ophthalmology · 2023Pooled it
- Ocular toxicity associated with Ethambutol in the South-East Asia Region.International ophthalmology · 2026Observational
- Preclinical pharmacokinetics/pharmacodynamics studies defining the role of ethambutol inAntimicrobial agents and chemotherapy · 2026Article
- Knowledge, Attitudes, and Practices Toward Drug-Induced Visual Impairment Due to Antitubercular Therapy Among Medical Officers of Primary Health Care Centers in Karnataka, South India.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Synergistic and additive effects of rifampicin, moxifloxacin, ethambutol, and azithromycin against M. simiae clinical isolates.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Review
- Ethambutol-Induced Optic Neuropathy: A Retrospective Study of Incidences and Risk Factors.Cureus · 2025Article
- Ethambutol optic neuropathy.Frontiers in neurology · 2025Review
- Identifying predictors of visual improvement in ethambutol optic neuropathy: insights from a 5-year retrospective analysis in a tertiary clinic in Indonesia.International journal of ophthalmology · 2025Article
- Article
- Tuberculosis-diabetes comorbidities: Mechanistic insights for clinical considerations and treatment challenges.World journal of diabetes · 2024Review
- Nationwide usage of ethambutol and incidence and screening practices of optic neuropathy.Frontiers in pharmacology · 2024Article
- Prevalence of visual impairment and eye diseases in Malaysia: A cross-sectional prospective study at the University of Malaya Medical Centre.Malaysian family physician : the official journal of the Academy of Family Physicians of Malaysia · 2024Article
- The Neuro-Ophthalmology of Tuberculosis.Neuro-ophthalmology (Aeolus Press) · 2024Review
- Adverse Ocular Effects of Systemic Medications.Life (Basel, Switzerland) · 2023Review
- Comment on: Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis, and management of ethambutol-induced optic neuropathy.Indian journal of ophthalmology · 2022Article
- Response to comment on: Ethambutol toxicity: Expert panel consensus for the primary prevention, diagnosis, and management of ethambutol-induced optic neuropathy.Indian journal of ophthalmology · 2022Article
- The Genetics of Ethambutol-Induced Optic Neuropathy: A Narrative Review.Neuro-ophthalmology (Aeolus Press) · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
11 authors at 7 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ethambutol use may lead to permanent vision loss by inducing a dose- and duration-dependent optic neuropathy. This has been of concern to ophthalmologists and physicians both; however, ethambutol continues to be used because of its anti-mycobacterial action with relative systemic safety. Recently, the guidelines of the Revised National Tuberculosis Control Programme of India have been revised to allow for fixed dose and longer duration of ethambutol use; this is likely to result in an increase in vision-threatening adverse effects. Taking cognizance of this, neuro-ophthalmologists, infectious disease specialists, and scientists met under the aegis of the Indian Neuro-Ophthalmology Society to deliberate on prevention, early diagnosis, and management of ethambutol-related toxic optic neuropathy. The recommendations made by the expert group focus on early suspicion of ethambutol toxicity through screening at the physician's office and opportunistic screening by the ophthalmologist. Further, they focus on an early diagnosis through identification of specific clinical biomarkers and on management in way of early stoppage of the drug and supportive therapy. This statement also describes the mechanism of reporting a case of toxic optic neuropathy through the Pharmacovigilance Programme of India and emphasizes the need for spreading awareness regarding vision-threatening adverse effects among patients and healthcare workers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.